Colon cancer-associated transcription 2 (CCAT2) was recently identified as a novel long noncoding RNA transcript encompassing the single-nucleotide polymorphism rs6983267. CCAT2 is overexpressed in colorectal cancer (CRC) where it promotes tumor growth, metastasis, and chromosomal instability, although the clinical relevance of this enhanced expression is unknown. In this retrospective study, CCAT2 expression was evaluated using real-time polymerase chain reaction in 149 CRC patients, and its associations with clinicopathological characteristics, outcome, rs6983267 genotypes, microsatellite status, DNA ploidy, and BubR1 expression were analyzed. CCAT2 expression in cancer tissue was significantly higher than in noncancer tissue (p < 0.001), particularly in cases of metastatic cancer (p < 0.001). However, relative CCAT2 expression levels and rs6983267 genotypes were not correlated with clinicopathological features or patient prognosis. CRC cases demonstrating high CCAT2 expression were all microsatellite stable (p < 0.005). Together, this indicates that CCAT2 expression was associated with microsatellite-stable CRC.

1.
American Cancer Society: Colorectal Cancer Facts and Figures 2013. Atlanta, GA, American Cancer Society, 2013.
2.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3.
Center MM, Jemal A, Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18:1688-1694.
4.
GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
5.
Takachi R, Tsubono Y, Baba K, et al: Red meat intake may increase the risk of colon cancer in Japanese, a population with relatively low red meat consumption. Asia Pac J Clin Nutr 2011;20:603-612.
6.
Mimori K, Tanaka F, Shibata K, Mori M: Review: Single nucleotide polymorphisms associated with the oncogenesis of colorectal cancer. Surg Today 2012;42:215-219.
7.
Haiman CA, Le Marchand L, Yamamato J, et al: A common genetic risk factor for colorectal and prostate cancer. Nat Genet 2007;39:954-956.
8.
Tomlinson I, Carvajal CL, Broderick P, et al: A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007;39:984-988.
9.
Takatsuno Y, Mimori K, Yamamoto K, et al: The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer. Ann Surg Oncol 2013;20:1395-1402.
10.
Sugimachi K, Niida A, Yamamoto K, et al: Allelic imbalance at an 8q24 oncogenic SNP is involved in activating MYC in human colorectal cancer. Ann Surg Oncol 2014;21:515-521.
11.
Bejerano G, Pheasant M, Makunin I, et al: Ultraconserved elements in the human genome. Science 2004;304:1321-1325.
12.
Calin GA, Liu CG, Ferracin M, et al: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007;12:215-229.
13.
Wojcik SE, Rossi S, Shimizu M, et al: Non-coding RNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis 2010;31:208-215.
14.
Ling H, Spisso R, Atlasi Y, et al: CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res 2013;23:1446-1461.
15.
Redis RS, Sieuwerts AM, Look MP, et al: CCAT2, a novel long non-cording RNA in breast cancer: expression study and clinical correlation. Oncotarget 2013;4:1748-1762.
16.
Zhao Y, Ando K, Oki E, et al: Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer. Anticancer Res 2014;34:5421-5427.
17.
Zhao Y, Oki E, Ando K, et al: The impact of a high-frequency microsatellite instability phenotype on the tumor related genetic differences in colorectal cancer. Cancer Genet Cytogenet 2010;196:133-139.
18.
Jass JR, Sobin LH: Histological Typing of Intestinal Tumours. WHO International Histological Classification of Tumours No 15, ed 2. Berlin, Springer, 1989.
19.
Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002.
20.
Ando K, Kakeji Y, Kitao H, et al: High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci 2010;101:639-645.
21.
Ikawa-Yoshida A, Ando K, Oki E, et al: Contribution of BubR1 to oxidative stress-induced aneuploidy in p53-deficient cells. Cancer Med 2013;2:447-456.
22.
Nakanishi R, Harada J, Tuul M, et al: Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. Int J Clin Oncol 2013;18:1042-1048.
23.
Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
24.
Furuya T, Uchiyama T, Murakami T, et al: Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res 2000;6:2815-2820.
25.
He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512.
26.
Bondi J, Bukholm G, Nesland JM, et al: Expression of non-membranous β-catenin and γ-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 2004;112:49-56.
27.
Saiki Y, Ishimura S, Mimori K, et al: Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol 2009;16:2638-2644.
28.
Tuupanen S, Turunen M, Lehtonen R, et al: The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009;41:885-890.
29.
Jass RJ: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-130.
30.
Menssen A, Epanchintsev A, Lodygin D, et al: c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 2007;3:339-352.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.